ORIC Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Thursday, January 2, 2020 Press Release
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., Jan. 2, 2020 /PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, MD, the Company's Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference. Dr. Chacko's presentation will take place on Tuesday, January 14, 2020, at 9:30 a.m. PST.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. ORIC's lead program, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to treatment resistance to multiple classes of anti-cancer therapeutics across a variety of solid tumors.  ORIC's pipeline also includes an orally bioavailable small molecule inhibitor of CD73, as well as other undisclosed programs targeting mechanisms of oncology therapeutic resistance. ORIC's scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. The company has assembled strong leadership and scientific teams, and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors and is headquartered in South San Francisco, California. For more information, please go to http://oricpharma.com/.

Contact:Dominic Piscitelli, Chief Financial Officer  231680@email4pr.com 650-388-5600

Cision View original content:http://www.prnewswire.com/news-releases/oric-pharmaceuticals-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300980212.html

SOURCE ORIC Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store